Kabipac Glucosa

Glucose monohydrate, the active ingredient in Kabipac Glucosa, is an excipient, solvent presented as a solution for injection for intravenous use. It provides glucose as an energy substrate for cellular metabolism and is used in the treatment of hypoglycemia, fluid and electrolyte replacement, and parenteral nutrition.

GNH USA supplies Kabipac Glucosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Kabipac Glucosa is used in clinical situations requiring intravenous glucose supplementation.

- Hypoglycemia: restores blood glucose levels in patients with low blood sugar. - Fluid and electrolyte replacement: supplies glucose as part of balanced IV fluids to support hydration and electrolyte balance. - Parenteral nutrition: provides an energy source in total parenteral nutrition regimens for patients unable to receive enteral feeding.

Intravenous administration of glucose solutions can be associated with several adverse reactions.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels. - Phlebitis: irritation of the vein at the infusion site. - Electrolyte imbalance: shifts in serum sodium or potassium. - Local swelling: mild edema at the injection site.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria, or anaphylaxis. - Hyperosmolar hyperglycemic state: severe hyperglycemia with dehydration. - Sepsis: contamination leading to bloodstream infection.

When using Kabipac Glucosa, clinicians should observe several safety measures.

- Patient monitoring: check blood glucose regularly during infusion. - Infusion rate: administer slowly to avoid rapid glucose spikes. - Fluid balance: adjust total fluid volume to prevent overload. - Compatibility: verify compatibility with other IV drugs before mixing. - Contraindications: avoid in patients with known glucose intolerance or severe hyperglycemia. - Store at ambient temperature: keep in original container, protect from light and moisture.

Glucose solutions may interact with other medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Insulin therapy: concurrent high‑dose insulin can cause severe hypoglycemia. - Sodium bicarbonate solutions: may precipitate when mixed with glucose solutions.

Moderate Interactions (Monitor Closely): - Diuretics: increase risk of electrolyte disturbances. - Beta‑adrenergic agonists: can alter glucose metabolism. - Corticosteroids: may raise blood glucose, requiring dose adjustment.